Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer

Investigational New Drugs

Volumn 31, Issue 2, 2013, Pages 435-442

  Schneider, Bryan J ^a   Lee, Julia Shin Jung ^b,c   Hayman, James A ^c   Chang, Andrew C ^d   Orringer, Mark B ^d   Pickens, Allan ^e   Pan, Charlie C ^f   Merajver, Sofia D ^c,g   Urba, Susan G ^c,g  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e EMORY UNIVERSITY HOSPITAL   (United States)

^f Bellin Health   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cisplatin; Esophageal cancer; Neoadjuvant chemoradiation; Paclitaxel; Tetrathiomolybdate

Indexed keywords

CERULOPLASMIN; CISPLATIN; PACLITAXEL; TETRATHIOMOLYBDIC ACID;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANASTOMOSIS LEAKAGE; ANEMIA; ANTIANGIOGENIC ACTIVITY; ARTICLE; BEDTIME DOSAGE; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CERULOPLASMIN BLOOD LEVEL; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; CONVALESCENCE; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS METASTASIS; ESOPHAGUS RESECTION; FATIGUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LETHARGY; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS INHIBITION; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT REFUSAL;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MOLYBDENUM; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 84879551228     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9864-0     Document Type: Article

References (22)

1. Jemal A, Siegel R, Xu J, et al. (2010) Cancer statistics. CA Cancer J Clin 60:277-300
2. Urba SG, Orringer MB, Ianettonni M, et al. (2003) Concurrent cisplatin, paclitaxel and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 98:2177-2183
3. Gaast AV, van Hagen P, Hulshof M, et al. (2010) Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. J Clin Oncol 28:15s, (Suppl; abstr 4004)
4. Sharma R, Yang GY, Nava HR, et al. (2009) A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC), J Clin Oncol 27:15s, (Suppl; abstr 15619)
5. Brewer GJ, Hedera P, Kluin KJ, et al. (2003) Treatment of Wilson's disease with tetrathiomolybdate III. Initial therapy in a total of 55 neurology affected patients and follow-up with zinc therapy. Arch Neurol 60:378-385
6. Brewer GJ, Askari F, Lorincz MT, et al. (2006) Treatment of Wilson's disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double blind study of treatment of neurologic presentation of Wilson's disease. Arch Neurol 63:521-527
7. Pan Q, Kleer CG, van Golen KL, et al. (2002) Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 62:4854-4859
8. Pan Q, Bao LW, Merajver SD (2003) Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFκB signaling cascade. Mol Canc Res 1:701-706
9. Brewer GJ, Dick RD, Grover DK, et al. (2000) Treatment of metastatic cancer with tetrathiomolybdate, and anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 6:1-10
10. Henry NL, Dunn R, Merajver S, et al. (2006) Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer. Oncology 71:168-175
11. Redman BG, Esper P, Pan Q, et al. (2003) Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 9:1666-1672
12. Gartner EM, Griffith KA, Pan Q, et al. (2009) A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-fluorouracil and leucovorin for metastatic colon cancer. Investig New Drugs 27:159-165
13. Brewer GJ (2003) Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation. J Cell Mol Med 7:11-20
14. Brewer GJ, Merajver S (1999) Treatment of metastatic cancer with the anticopper, antiangiogenic, tetrathiomolybdate. J Investig Med 47:223A
15. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephro 16:31-41
16. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
17. Saltz LB, Clarke S, Diaz-Rubio E, et al. (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2019
18. Sandler A, Gray R, Perry MC, et al. (2007) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550
19. Miller K, Wang M, Gralow J, et al. (2007) Paclitaxel Plus Bevacizumab Versus Paclitaxel Alone for Metastatic Breast Cancer. N Engl J Med 35:2666-2676
20. Hassouneh B, Islam M, Nagel T, et al. (2007) Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol Cancer Ther 6:1039-1045
21. Pass HI, Brewer GJ, Dick R, et al. (2008) A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg 86:383-390
22. Cunningham D, Allum WH, Stenning SP, et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20